

# Aquatherapy in the pulmonary rehabilitation

#### Maria Barnai University of Szeged

Email: barnaim@etszk.u-szeged.hu

## The three main diseases

EWAC .

MEDICAL

- Chronic obstructive pulmonary disease COPD
- Asthma bronchiale
- Cystic fibrosis CF

#### Guidelines




Brithish ACPCF 2002 (physioth.) Brithish COPD 2003 (med.) Brithish Asthma 2005 (med.)

Holland COPD 2003 (physioth) Hungarian COPD 2004 (med.)

COPD



- 4.-6. most frequent cause of death on the world
- Treatment with medicines is very expensive (2,5 x asthma br.) – not effective
- Prevalens
  - 900 000 (England) true number may be: 1,5 mill.
  - 54 000 (Hungary) 4-500 000



#### Asthma bronchial



- Chronic inflammatory disorder of airways
- Airway obstruction
- Response to a variety of stimuli
  - Allergen atopic
  - Exercise induced asthma EIA
  - Psychogenic factors
- Reversibility spontaneously or with treatment

### Cystic fibrosis



- Genetic disorder with Ca<sup>++</sup> channel problems – progressive and fatal
- Pulmonary features: multifarious lung image
  - Bronchitis (acute or chr.)
  - Emphysema
  - Fibrosis
  - Lot of mucus (dry and adhesive)
- Cor pulmonale
- Complex digestion insufficiency
  - Lack of proteins, carbohydrates, fats, vitamins, minerals



#### May be present

We get you moving ASTH. CF

EWAC . MEDICAL

|                                | COPD | ASTH. | CF  |
|--------------------------------|------|-------|-----|
| Dyspnoea rest/exercise         | +/+  | +/+   | +/+ |
| Hyperinflated chest            | +    | +     | +   |
| Coughing                       | +    | +     | +   |
| Wheeze or quiet breath sounds  | +    | +     | +   |
| Purse lip breathing            | +    | +     | +   |
| Use of accessory muscles       | +    | +     | +   |
| Paradox movement of lower ribs | +    | +     | +   |
| Peripheral oedema              | +    | +     | +   |
| Decreased physical condition   | +    | +     | +   |
| Depression-socially isolated   | +    | +     | +   |

#### Causes

COPD ASTR. CF

- Smoking (10-15% of COPD patients have never smoked\*)
- Genetic predisposition
- Hypersensitivity allergens
- Respiratory infections

\*Fletcher C, Peto R: The natural history of chronic airflow obstruction. BMJ 1:1645-1648, 1977



#### Noisy breathing


## Because of airway obstruction:

Reversible or not


MEDICAL

EWAC

We get you moving



Normal airway



Obstructed airway

#### Dyspnea



- Dyspnoea
  - longer expiration > 6s
  - Hard expiration
  - Hard inspiration
  - In rest or effort
  - Position supported breath
  - Pursed-lips breathing (auto PEP)



#### Failure of respiratory system

- Chest deformity –
   hyperinflation
- Horizontal ribs position
- Shortened intercostals muscles
- Deep position of the diaphragm
- Decreased ROM of ribs rigid thorax
- Increased energy requirement of expiration and inspiration




EWAC

MEDICAL



Tables of Moses

#### Normal Asthma CF



EWAC MEDICAL

you moving



#### CF: 12 Year old boy

#### Thorax



Hyperinfated chest in exacerbation

The chest after treatment (with PEP)




#### We get you moving

MEDICAL

Young adult CF boy: Improved kyphosis, and visible accessory breathing muscles

EWAC .







COPD bronchiatic form Hyperinflated chest shortened neck, overweight

## Lung function



- COPD: not typical
  - FEV1 ↓ > 80% of pred. ↓50 ml/yrs (norm: 25-30)
  - FEV1/FVC↓ 70-30% (norm≈80%)
- Asthma: (in attack)
  - FEV1  $\downarrow\downarrow$
  - FVC norm or  $\downarrow$
  - FEV1/FVC  $\downarrow \downarrow \downarrow$  PEF  $\downarrow \downarrow$
- CF: variable
  - $RV \uparrow \uparrow \uparrow$  (maybe obstructive + restrictive too)


## COPD classification We get you moving

EWAC .

MEDICAL

FEV1 (% of predicted value)

- European Respiratory Society
  - mild ≥ 70%
  - moderately severe 50-69%
  - severe 35-49%
- American Thoracic Society
  - phase 1 ≥ 50%
  - phase 2 35-49%
  - phase 3 < 35%</p>



American Thoracic Society/European Respiratory Society: Skeletal muscle dysfunction in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 159:S1-S40, 1999

#### Muscle fatigue is caused by

MEDICAL

EWAC

- the effort dyspnoea
- reduced aerobic capacity \*(Fiber I decreases, Fiber IIa increases)
- lactic acid increased at an earlier stage during exercise
- cardiac decompensation
- corticosteroid use
- impaired nutritional stage
- \* Montes de Oca et al Respiratory Medicine (2006) 100, 1800–1806

### Goals of the physiotherapy

MEDICAL


EWAC

- to improve mucus clearance;
- to improve exercise capacity;
- to reduce dyspnoea; and
- to promote compliance with therapy.

#### Expectoration



- Increase the viscosity of mucus of airways
- Increase the airflow during expiration
- Increase the airway diameter (prevent the collapse, decrease the obstruction)
- Increase the effectivity of cough



## Respiratory Physiotherapy

MEDIC

EWAC


- has three main aims:
  - To help reduce the work of breathing associated with respiratory disease
  - To help restore patients' maximal function
  - To help improve peripheral and respiratory muscle weakness

#### Core treatments delivered by physiotherapists include: get you moving

- Techniques to reduce the work of breathing
  - relaxed breathing control in combination with positioning to maximise the function of the respiratory muscles and enhance diaphragmatic displacement.
  - In chronic asthma, the use of diaphragmatic breathing has shown a significant benefit on health related quality of life.
  - Pursed Lip Breathing techniques may be effective in helping patients manage breathlessness although data is limited.

## Positive expiratory pressure

- 10–20 cmH2O
- respiratory tract dilatation caused by increased expiratory airway pressure
- Flutter + airway vibration are thought to improve mucus transport.




MEDICAL


EWAC



#### PEP in water

Blowing bubbles Breath control Expiration under water during swimming





MEDICAL

EWAC .

Veget you moving

# Mobilization of the thorax

Manual mobilization Active movements Stretching Flutter





EWAC

MEDICAL








## Mobilization of the thorax you moving

16 patients with COPD (mean aged: 60,1 years, 48-77)



Cycle ergometer training for both groups

MEDICAL

EWAC

- 3 times a week for 8 weeks
- daily session: 40 minutes


|                      | FEV1<br>% pred | Tiff<br>(FEV1/VC) |
|----------------------|----------------|-------------------|
| Mobilized G<br>(n=8) | 41 - 64        | 43 - 49           |
| Control G<br>(n=8)   | 34 - 68        | 39 - 66           |

Barnai et al Barcelona WCPT Congr. 2003

#### Mobilization of the thorax

MEDICAL

EWAC



Improvement of the mobility of the thorax has a favourable influence on the exercise tolerance and fatigue without significantly influencing the results of the lung function, and peak oxygen consumption.

Barnai et al Barcelona WCPT Congr. 2003

## Chest mobilization in Water

MEDIC

EWAC

- Water gives an external pressure (hydrostatic) to
  - Chest wall
  - Abdomen diaphragm
  - Deeper expiration beeper inspiration
  - Reduced RV
  - Strengthening of the inspiratory muscles
  - + active expiration against the resistance of the water

#### The water optimizes the diaphragment function We get you moving

- Elongates of the low positioned diaphragm:
  - contraction of the abdominal muscles during expiration
  - hydrostatic pressure on the wall of abdomen
- Gives a resistance against the expiration
- This action facilitates the diaphragm function. The next inspiration start from a better diaphragm position

The accessory muscles of respiration can provide more force if the arms are anchored in position, for example during swimming

# Chest mobilization in water

















# Chest mobilization in Water





## Effect of dry and humid air

EIA – dry inhaled air provoke the asthmatic airway reaction during exercise

Study: 9 asthmatic children (9-15 years old)

Treadmill running
 Bronchoconstriction

Swimming exercise No bronchoconstriction

EWAC .

MEDICAL

Humidity: 25-30%

80-90%

conditions were same: intensity, duration, temperature of air, and water

• Inbar Eur J Appl Physiol 1980

Main points of treatment for moving improving exercise capacity. you moving

- A good breathing technique is necessary for training to build exercise capacity.
- Functions that are important for physical performance :
  - muscle strength,
  - muscle endurance,
  - speed,
  - coordination
  - and flexibility.



### Type of exercise

- circuit training,
- sports and games,
- Swimming or exercise in water

 Patient become more active and independent

#### Measurement



- strength and endurance of skeletal muscles with dynamometer
- respiratory muscles: strength and endurance measurement with mouth pressure meter
- general endurance measurement:
  - 6 or 12 minute walking test (MWT), shuttle walk test,
  - cycle ergometer / treadmill endurance test
  - Borg scale
- dyspnoea: dyspnoea scale

#### Dyspnoea scale



Grade Degree of breathlessness related to activities

- 1 Not troubled by breathlessness except on strenuous exercise
- 2 Short of breath when hurrying or walking up a slight hill
- 3 Walks slower than contemporaries on the level because of
- breathlessness, or has to stop for breath when walking at own
- pace
- 4 Stops for breath after walking about 100m or after a few
- minutes on the level
- 5 Too breathless to leave the house, or breathless when
- dressing or undressing
- (Fletcher CM et al. 1959)

### Effects of physical activity in COF

| Author                                    | Study design | n  | Studied parameters  | Significant results   |
|---|--------------|----|---|---|
| Cambach <i>et al</i> ¹º<br>(Netherlands)  | RCT          | 23 | Exercise tolerance (CE, 6MWT),<br>QOL (CRQ), dyspnoea (CRQ)   | Improved exercise tolerance (CE, not 6MWT), QOL<br>and dyspnoea after three months, and again three<br>months later (CE and 6MWT), QOL and dyspnoea |
| Clark e <i>t al</i> <sup>11</sup><br>(UK) | RCT          | 48 | Exercise tolerance (CE, WT)                                   | Improved exercise tolerance after three months (WT, not CE)   |
| Clark e <i>t al</i> 12<br>(UK)            | RCT          | 43 | Exercise tolerance (WT)                                       | Improved exercise tolerance after three months (WT)   |
| Grosbois <i>et al</i> ¹³<br>(France)      | CCT          | 58 | Exercise tolerance (CE),<br>dyspnoea (VAS)                    | Improved exercise tolerance in subgroups after 18<br>months (CE); no difference in dyspnoea   |
| Ringbaek e <i>t al</i> 14<br>(Denmark)    | RCT          | 38 | Exercise tolerance (6MWT),<br>dyspnoea (BS), QOL (SGRQ, PWBI) | No effects on exercise tolerance, dyspnoea or QOL<br>after two months   |

EWAC .

MEDIC

CE = cycle ergometry (physiological parameters, maximal exertion in watts); 6MWT = six-minute walking test (distance in metres); WT = walking test (endurance in joules); CRQ = chronic respiratory disease questionnaire (including dyspnoea score); SGRQ = St George's respiratory questionnaire; PWBI = psychological wellbeing index; VAS = visual analogue scale; BS = Borg scale.

#### Asthma and swimming

Eight children with mild or moderate asthma participated in swimming training every days for six weeks.




Figure 3 Mean (SD) changes in work load by swimming ergometer before and after training in training group (n = 8) and control group (n = 8).

Figure 4 Mean (SD) changes in work load by cycle ergometer before and after training in training group (n = 8) and control group (n = 8).

EWAC

MEDICAL

# Improve the physical activity and evercise tolerance We get you moving

- Mild and moderate asthma br.
- Swimming: 3 years two times a week
- Results of Cooper test 12 min running:

|           | number | age  | 12min running |
|-----------|--------|------|---------------|
| Swimmer/  | 51     | 8-22 | 2358,4 m      |
| asthmatic |        |      | (± 400,6)     |
| Not sw./  | 28     | 9-22 | 2214,5 m      |
| asthmatic |        |      | (± 426,6)     |
| Not sw./  | 179    | 8-22 | 1850,8 m      |
| healthy   |        |      | (± 408,3)     |

• Bellanyi, Gyene et al (2007 Orvosi hetilap)

#### Cardiorespiratory parameters at rest on land and in water (n=20) COPD We get you moving


Water Parameter Land p-value HR beats/min 82±22 86±18 NS  $164 \pm 17$  SBP mmHg 150±18 < 0.001 DBP mmHg 87±10 81±11 0.01 ulletVentilation breaths/min  $18.5\pm5.2$  $18.5 \pm 4.3$ NS Sa,02 %  $94 \pm 4$  $94 \pm 4$ NS VC L 2.19±0.78  $1.92\pm0.79$ < 0.001 FEV1 L  $1.08 \pm 0.53$ < 0.001  $0.93 \pm 0.54$ FEV1/VC 0.51±0.12  $0.48 \pm 0.13$ NS PEF L/min 120±82  $99 \pm 83$ < 0.001

J Perk et al Eur Respir J., 1996, 9, 248–252.


# Parameters during 15 min dynamic submaximal arm exercise on land and in water (n=20) GORD noving

|                          | Land   | Water  | p-value |
|--------------------------|--------|--------|---------|
| Heart rate (HR)beats/min |        |        |         |
| Exercise I               | 111±22 | 115±20 | NS      |
| Exercise II              | 119±25 | 116±21 | NS      |
| ExerciseIII              | 114±24 | 115±23 | NS      |
| ΔResting HR              | 13±9   | 7±6    | <0.05   |
| Sa,O2 %                  |        |        |         |
| Exercise I               | 93±5   | 93±4   | NS      |
| Exercise II              | 95±4   | 93±3   | <0.05   |
| Exercise III             | 94±4   | 94±3   | NS      |
| Borg rating of effort    |        |        |         |
| Exercise I               | 12±2   | 14±2   | 0.01    |
| Exercise II              | 15±2   | 15±2   | NS      |
| Exercise III             | 14±2   | 14±3   | NS      |
| Borg rating of dyspnoea  |        |        |         |
| Exercise I               | 3±1    | 4±1    | <0.01   |
| Exercise II              | 4±1    | 5±2    | <0.01   |
| Exercise III             | 4±2    | 4±1    | NS      |


J Perk et al Eur Respir J., 1996, 9, 248–252.



Rowing




lifting



Horizontal weight pulling 3/2min

## Effects of swimming training


#### Training on the swimming ergometer - high intensity 2\*15 min/day \* 6 day /week \* 6 week



• Tanaka and M Shindo et al (Thorax 1999;54;196-201)

# Training of COPD on land and we get you moving

High intensity physical group training in water (water group) or on land (land group) was performed for 12 weeks, three times per week, 45 min per session



Wadell et al Respiratory Medicine (2004) 98, 428–438

#### Incremental shuttle walk test Endurance shuttle walk test (COPD) ou moving

|          |  | Control group $(n=12)$                  | Water group                                  |   | Land group                                |  |  |
|----------|--|---|--|---|---|--|--|
|          |  |   | Intention to treat $(n = 15)$                | On treatment $(n = 12)$                           | Intention to treat $(n = 14)$             | On treatment $(n=12)$                      | Between group<br>comparisons   |
| ISWT (m) | Baseline<br>3 months<br>Within group<br>comparison | 345 (180–550)<br>320 (200–500)<br>ns    | 270 (200–540)<br>340 (150–540)<br>ns         | 270 (200–540)<br>345 (260–540)<br>ns              | 350 (130–570)<br>390 (140–590)<br>P=0.008 | 380 (130–570)<br>420 (140–590)<br>P= 0.003 | ns   |
|          | Difference<br>Baseline/3 mo                        | -5 (-110-80)                            | 20 (-140-110)                                | 55 (-90-110)                                      | 20 (-20-130)                              | 25 (0–130)                                 | $P = 0.03^{\rm a}$<br>$P = 0.008^{\rm b}$  |
| ESWT (m) | Baseline<br>3 months<br>Within group<br>comparison | 1047 (116–1538)<br>599 (176–1446)<br>ns | 458 (133–1364)<br>1060 (315–1846)<br>P=0.001 | ★<br>562 (133–1364)<br>1319 (315–1846)<br>P=0.002 | 576 (85–1905)<br>512 (209–1905)<br>ns     | 686 (85–1905)<br>747 (209–1905)<br>ns      | ns   |
|          | Difference<br>Baseline/3 mo                        | -40 (-890-444)                          | 164 (8–1454)                                 | 179 (8–1454)                                      | 53 (-473-704)                             | 53 (-473-704)                              | $P = 0.001^{\circ}$<br>$P = 0.009^{d}$<br>$P = 0.001^{\circ}$<br>$P = 0.007^{\circ}$ |

Wadell et al Respiratory Medicine (2004) 98, 428–438



|                                      |  | Control group $(n = 12)$                      | Water group                               |   | Land group                                  |   |                              |
|--------------------------------------|--|---|---|---|---|---|------------------------------|
|                                      |  |   | Intention to treat $(n=15)$               | On treatment $(n=12)$                     | Intention to treat $(n=14)$                 | On treatment $(n=12)$                       | Between group<br>comparisons |
| Time cycled (s)                      | Baseline<br>3 months<br>Within group<br>comparison | 495 (230–1260)<br>525 (240–1440)<br>ns        | 520 (360–720)<br>580 (380–900)<br>P=0.004 | 520 (380–720)<br>595 (390–900)<br>P=0.008 | 540 (260–1170)<br>575 (270–1300)<br>P=0.033 | 540 (350–1170)<br>595 (390–1300)<br>P=0.016 | ns                           |
|                                      | Difference<br>Baseline/3 mo                        | 20 (-110-180)                                 | 40 (-30-180)                              | 85 (-30-180)                              | 25 (-50-170)                                | 40 (-30-170)                                | ns                           |
| Load <sub>peak</sub> (W)             | Baseline<br>3 months<br>Within group<br>comparison | 60 (40–140)<br>60 (40–160)<br><i>P</i> =0.046 | ★<br>60 (40-80)<br>80 (60-100)<br>P=0.008 | ★<br>60 (60–80)<br>80 (60–100)<br>P=0.014 | ★ 60 (40–140) 80 (40–160) P = 0.008         | €0 (40–140)<br>80 (60–160)<br>P=0.008       | ns                           |
|                                      | Difference<br>Baseline/3 mo                        | 0 (0–20)                                      | 0 (0–20)                                  | 10 (0–20)                                 | 10 (0–20)                                   | 20 (0–20)                                   | ns                           |
| VO <sub>2 peak</sub> (ml∕<br>kg∙min) | Baseline   | ★<br>16.6 (10.8–24.9)                         | 15.6 (13.0–23.1)                          | 15.5 (13.2–23.1)                          | 17.7 (13.3–27.3)                            | 18.9 (14.6–27.3)                            | ns                           |
| 5                                    | 3 months<br>Within group<br>comparison             | 18.0 (11.5–28.7)<br>P=0.018                   | 16.9 (14.0–26.4)<br>P=0.008               | 16.9 (14.0–26.4)<br>P=0.004               | 17.7 (13.3–34.1)<br>ns                      | 19.8 (13.9–34.1)<br>ns                      |                              |
|                                      | Difference<br>Baseline/3 mo                        | 0.7 (-0.7-3.8)                                | 1.5 (-1.9-3.5)                            | 2.1 (-0.5-3.5)                            | 0.6 (-3.9-6.8)                              | 0.6 (-3.9-6.8)                              | ns                           |